9/14/2026
Psyence BioMed launches US ibogaine subsidiary
New Texas-based entity to spearhead ibogaine research and development in the US.
Topic archive
18 stories
9/14/2026
New Texas-based entity to spearhead ibogaine research and development in the US.
9/14/2026
New subsidiary aims to centralize ibogaine supply and regulatory efforts in the U.S.
9/14/2026
Texas Ibogaine Research Corporation to spearhead U.S. ibogaine development efforts.
9/1/2026
The study aims to explore ibogaine's potential for treating PTSD and addiction.
8/19/2026
U.S. federal actions could accelerate ibogaine's medical potential
8/19/2026
Company aligns with U.S. efforts to advance ibogaine research.
8/10/2026
Arizona funds first U.S. ibogaine trial for traumatic brain injuries, starting 2027.
8/7/2026
Rick Perry and Bryan Hubbard lead efforts to legitimize ibogaine in Texas.
8/7/2026
Study explores ibogaine's potential for TBI, amid safety concerns and federal illegality.
7/29/2026
State-led ibogaine study in Texas receives federal funding, advancing research into opioid treatment.
7/29/2026
State-led ibogaine study in Texas gains federal backing, marking a significant research development.
7/29/2026
The new program aims to explore ibogaine's potential in treating opioid addiction.
7/27/2026
New NDAA provision aims to expand ibogaine access for veterans.
7/22/2026
Proposed NDAA amendment aims to expand treatment options for PTSD and TBI.
7/16/2026
Mayor Gina Ortiz Jones pushes for psychedelic trials to aid veterans.
7/16/2026
Veterans report transformative effects from psychedelic treatment.
7/16/2026
Veterans report transformative effects from psychedelic therapy.
7/16/2026
Veterans share recovery stories, highlighting ibogaine's potential.